人黑色素瘤細胞MeWo

細胞名稱

人黑色素瘤細胞MeWo

貨物編碼

BFN60810339

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   3類

培養體系

90%DMEM+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人黑色素瘤細胞MeWo取自78歲男性，該細胞源于ECACC

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: ERK genetic alteration cell panel (ATCC TCP-1033).

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Doubling time: ~32 hours (PBCF).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: HLA class I peptidome analysis by proteomics.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突變

Homozygous for CDKN2A p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu; c.280_281CC>TT) (PubMed=17260012; PubMed=23851445; ATCC).

FGFR1 p.Pro252Ser (c.754C>T) (PubMed=23851445).

Heterozygous for MAPK3 p.Pro246Ser (c.736C>T) (ATCC).

TP53 p.Gln317Ter (c.949C>T) (PubMed=17260012; PubMed=23851445).

HLA信息

Class I

HLA-A        A*02:01,26:01

HLA-B        B*14:02,38:01

HLA-C        C*08:02,12:03

Class II

HLA-DP        DPB1*04:01,04:02

HLA-DQ        DQB1*03:01:01,05:01

HLA-DR        DRB1*11:01,01:02

STR信息

Amelogenin        X,Y

CSF1PO        12 (ATCC; CLS; Cosmic-CLP; JCRB; PubMed=25877200)

10,12 (ESTDAB)

D3S1358        17

D5S818        12,13

D7S820        10,12

D8S1179        13,15

D13S317        8 (Cosmic-CLP; ESTDAB)

8,9 (ATCC; CLS; JCRB; PubMed=25877200)

D16S539        10,12

D18S51        14,17

D21S11        30,32.2

FGA        22

Penta D        10

Penta E        5 (CLS)

5,15 (PubMed=25877200)

TH01        7,9

TPOX        8,10 (ATCC; CLS; Cosmic-CLP; JCRB; PubMed=25877200)

9,11 (ESTDAB)

vWA        15

參考文獻

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)